Actualités Medexus Pharmaceuticals Inc - MDP | Actions Toronto Stock Exchange

Donnez du pouvoir à votre portefeuille : discussions en temps réel et idées de trading exploitables.

Premium

Medexus Pharmaceuticals Announces Pricing of $30 Million Overnight Marketed Public Offering of Common Shares

The Base Shelf Prospectus is accessible, and the Prospectus Supplement will be accessible within two business...

Medexus Pharmaceuticals Announces Overnight Marketed Public Offering of Common Shares

NOT FOR DISTRIBUTION TO UNITED STATES TORONTO and CHICAGO, Jan. 27, 2025 (GLOBE NEWSWIRE) -- Medexus...

Medexus Pharmaceuticals Announces C$10 Million Bought-Deal Public Offering of Units

TORONTO and CHICAGO, Sept. 05, 2023 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals Inc. ("Medexus" or the...

Medexus to Participate in the 2023 Bloom Burton & Co. Healthcare Investor Conference

TORONTO and CHICAGO, April 18, 2023 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals (TSX: MDP; OTCQX: MEDXF) is...

Medexus Expects Record Revenue for Fiscal Year 2023 and Provides Business Update

TORONTO and CHICAGO, April 11, 2023 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals (TSX: MDP; OTCQX: MEDXF) is...

Medexus Announces New License Deal for Topical Terbinafine

TORONTO and CHICAGO, March 22, 2023 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals (TSX: MDP; OTCQX: MEDXF) is...

Medexus Announces US$58.5 million in New Credit Facilities

TORONTO and CHICAGO, March 08, 2023 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals (TSX: MDP; TSX: MDP.DB;...

Medexus to Participate in 35th Annual Roth Conference

TORONTO and CHICAGO, March 06, 2023 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals (TSX: MDP; OTCQX: MEDXF) is...

Medexus Announces Another Record Quarter with Fiscal Q3 2023 Revenue of US$28.7 Million, a 35% Increase Over Fiscal Q3 2022

Results reflect growth across all leading prescription products, demonstrating continued track record of strong...

Medexus Welcomes Two New Board Members

Harmony P. Garges MD MPH and Menassie Taddese MBA appointed to Medexus’s board of directors Appointments...

Medexus Secures Public Reimbursement for Cuvposa® in Quebec

TORONTO and CHICAGO, Feb. 01, 2023 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals (Medexus) (TSX: MDP...

Medexus Schedules Third Fiscal Quarter 2023 Conference Call

TORONTO and CHICAGO, Jan. 31, 2023 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals (Medexus) (TSX: MDP...

Medexus Expects Record Revenue for Fiscal Q3 2023 and Provides Business Update

TORONTO and CHICAGO, Jan. 12, 2023 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals (Medexus) (TSX: MDP...

Medexus Announces Strongest Quarter in Company History with Fiscal Q2 2023 Revenue of US$27.7 Million, a 55% Increase Over Fiscal Q2 2022

Results reflect strong growth across all leading prescription products, including IXINITY, Rupall, and Gleolan...

Medexus Schedules Second Quarter 2023 Conference Call

TORONTO and CHICAGO, Nov. 02, 2022 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals (Medexus) (TSX: MDP...

Forums

Afficher les forums

Aucune Discussion Trouvée

Ajouter une Discussion

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Medexus Pharmaceuticals Inc (MDP)

Donnez du pouvoir à votre portefeuille : discussions en temps réel et idées de trading exploitables.

MDP Actualités

Medexus Pharmaceuticals Announces Pricing of $30 Million Overnight Marketed Public Offering of Common Shares

Medexus Pharmaceuticals Announces Overnight Marketed Public Offering of Common Shares

Medexus Pharmaceuticals Announces C$10 Million Bought-Deal Public Offering of Units

Medexus to Participate in the 2023 Bloom Burton & Co. Healthcare Investor Conference

Medexus Expects Record Revenue for Fiscal Year 2023 and Provides Business Update

Medexus Announces New License Deal for Topical Terbinafine

Medexus Announces US$58.5 million in New Credit Facilities

Medexus to Participate in 35th Annual Roth Conference

Medexus Announces Another Record Quarter with Fiscal Q3 2023 Revenue of US$28.7 Million, a 35% Increase Over Fiscal Q3 2022

Medexus Welcomes Two New Board Members

Medexus Secures Public Reimbursement for Cuvposa® in Quebec

Medexus Schedules Third Fiscal Quarter 2023 Conference Call

Medexus Expects Record Revenue for Fiscal Q3 2023 and Provides Business Update

Medexus Announces Strongest Quarter in Company History with Fiscal Q2 2023 Revenue of US$27.7 Million, a 55% Increase Over Fiscal Q2 2022

Medexus Schedules Second Quarter 2023 Conference Call

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Medexus Pharmaceuticals Inc (MDP) Actualités

Medexus Pharmaceuticals Inc (MDP)

Donnez du pouvoir à votre portefeuille : discussions en temps réel et idées de trading exploitables.

MDP Actualités

Medexus Pharmaceuticals Announces Pricing of $30 Million Overnight Marketed Public Offering of Common Shares

Medexus Pharmaceuticals Announces Overnight Marketed Public Offering of Common Shares

Medexus Pharmaceuticals Announces C$10 Million Bought-Deal Public Offering of Units

Medexus to Participate in the 2023 Bloom Burton & Co. Healthcare Investor Conference

Medexus Expects Record Revenue for Fiscal Year 2023 and Provides Business Update

Medexus Announces New License Deal for Topical Terbinafine

Medexus Announces US$58.5 million in New Credit Facilities

Medexus to Participate in 35th Annual Roth Conference

Medexus Announces Another Record Quarter with Fiscal Q3 2023 Revenue of US$28.7 Million, a 35% Increase Over Fiscal Q3 2022

Medexus Welcomes Two New Board Members

Medexus Secures Public Reimbursement for Cuvposa® in Quebec

Medexus Schedules Third Fiscal Quarter 2023 Conference Call

Medexus Expects Record Revenue for Fiscal Q3 2023 and Provides Business Update

Medexus Announces Strongest Quarter in Company History with Fiscal Q2 2023 Revenue of US$27.7 Million, a 55% Increase Over Fiscal Q2 2022

Medexus Schedules Second Quarter 2023 Conference Call

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Supprimer les publicités